Venrock Adviser, LLC 13F holdings, Q4 2024
Holdings as of December 31, 2024 · filings on SEC EDGAR · latest filing →
Venrock Adviser, LLC disclosed 37 US equity positions worth $1.5bn in its Q4 2024 13F filing. The largest position was APGE at 26.4% of the reported book, followed by OCUL and ELVN. Against the Q3 2024 filing, it opened 3 new positions, added to 4 and reduced 10 among the top 37 holdings.
What did Venrock Adviser, LLC own in Q4 2024? Top 37 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2024 |
|---|---|---|---|---|---|---|---|
| 1 | APGE APOGEE THERAPEUTICS INC | Healthcare | 26.4% | $384.7m | 8,493,321 | 0% | held |
| 2 | OCUL OCULAR THERAPEUTIX INC | Healthcare | 7.5% | $109.0m | 12,762,462 | 0% | held |
| 3 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 6.2% | $90.6m | 4,026,331 | 0% | held |
| 4 | PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 5.2% | $76.2m | 989,985 | 40% | added |
| 5 | VRDN VIRIDIAN THERAPEUTICS INC | Healthcare | 5.1% | $74.4m | 3,882,709 | 0% | held |
| 6 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 4.4% | $63.7m | 3,285,620 | 6% | added |
| 7 | SYRE SPYRE THERAPEUTICS INC | 4.3% | $62.5m | 2,685,448 | 0% | held | |
| 8 | PHVS PHARVARIS N V | 4.2% | $61.7m | 3,220,130 | -5% | reduced | |
| 9 | 4XC1 KALVISTA PHARMACEUTICALS INC | 3.6% | $52.9m | 6,249,731 | 0% | held | |
| 10 | DYN DYNE THERAPEUTICS INC | Healthcare | 3.5% | $51.2m | 2,173,913 | 0% | held |
| 11 | COGT COGENT BIOSCIENCES INC | Healthcare | 3.0% | $44.3m | 5,684,411 | 0% | held |
| 12 | ERAS ERASCA INC | Healthcare | 2.8% | $40.7m | 16,216,216 | 0% | held |
| 13 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 2.6% | $38.0m | 1,744,373 | 0% | held |
| 14 | UPB UPSTREAM BIO INC | 2.6% | $37.7m | 2,295,319 | – | new | |
| 15 | ORIC ORIC PHARMACEUTICALS INC | Healthcare | 2.4% | $35.5m | 4,394,527 | 0% | held |
| 16 | ENGENE HOLDINGS INC | 2.3% | $33.6m | 5,046,414 | 42% | added | |
| 17 | MERUS N V | 1.7% | $24.9m | 592,411 | -35% | reduced | |
| 18 | CATBUSD ASTRIA THERAPEUTICS INC | 1.5% | $22.0m | 2,457,348 | -29% | reduced | |
| 19 | CDTX CIDARA THERAPEUTICS INC | 1.4% | $20.6m | 765,723 | – | new | |
| 20 | CGEM CULLINAN THERAPEUTICS INC | Healthcare | 1.2% | $16.8m | 1,379,965 | 0% | held |
| 21 | FDMT 4D MOLECULAR THERAPEUTICS IN | 1.1% | $16.4m | 2,952,371 | -33% | reduced | |
| 22 | ARTV ARTIVA BIOTHERAPEUTICS INC | 1.1% | $16.2m | 1,609,569 | 0% | held | |
| 23 | MERSANA THERAPEUTICS INC | 1.0% | $14.7m | 10,257,790 | -9% | reduced | |
| 24 | ABVX ABIVAX SA | 0.7% | $9.9m | 1,345,780 | 0% | held | |
| 25 | AQST AQUESTIVE THERAPEUTICS INC | 0.6% | $9.4m | 2,629,786 | -53% | reduced | |
| 26 | APLT APPLIED THERAPEUTICS INC | 0.6% | $8.6m | 9,990,591 | 2% | added | |
| 27 | PERCEPTIVE CAP SOLUTIONS COR | 0.5% | $7.6m | 750,000 | 0% | held | |
| 28 | 430 TERNS PHARMACEUTICALS INC | 0.4% | $6.0m | 1,077,090 | -68% | reduced | |
| 29 | TSHA TAYSHA GENE THERAPIES INC | Healthcare | 0.4% | $5.6m | 3,225,180 | -64% | reduced |
| 30 | TRVI TREVI THERAPEUTICS INC | Healthcare | 0.4% | $5.2m | 1,266,457 | -63% | reduced |
| 31 | ZURA ZURA BIO LTD | Healthcare | 0.3% | $5.1m | 2,023,166 | 0% | held |
| 32 | IPSC CENTURY THERAPEUTICS INC | Healthcare | 0.3% | $4.0m | 3,957,186 | -27% | reduced |
| 33 | CASIF CASI PHARMACEUTICALS INC | 0.2% | $2.8m | 987,259 | 0% | held | |
| 34 | TNYA TENAYA THERAPEUTICS INC | 0.2% | $2.2m | 1,555,556 | 0% | held | |
| 35 | TENX TENAX THERAPEUTICS INC | 0.1% | $1.3m | 208,333 | 0% | held | |
| 36 | GLYCEUR GLYCOMIMETICS INC | 0.1% | $747.0k | 3,000,000 | – | new | |
| 37 | TIL INSTIL BIO INC | 0.0% | $633.3k | 33,177 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.